Wang Hui, Chang Yanhua, Liang Hui
Hui Wang, Department of Urology Surgery, Binzhou People's Hospital, Shandong 256610, China.
Yanhua Chang, Department of Urology Surgery, Binzhou People's Hospital, Shandong 256610, China.
Pak J Med Sci. 2017 Jul-Aug;33(4):988-992. doi: 10.12669/pjms.334.12757.
To analyze the clinical effect of tamsulosin and Solifenacin in the treatment of benign prostatic hyperplasia in combination with overactive bladder and its safety. Another objective was to investigate the clinical effect and safety of mega dose of tamsulosin in the treatment of benign prostatic hyperplasia in combination with overactive bladder.
One hundred and twenty-four patients who were admitted to the Dept. of Urology at Binzhou People's Hospital, , China with confirmed benign prostatic hyperplasia (BPH) with overactive bladder were randomly divided into two groups. Sixty-two patients in the control group were treated with tamsulosin, while sixty-two patients in the observation group were treated with tamsulosin in combination with solifenacin. The treatment of both groups lasted for 12 weeks. The effect and adverse reaction were compared between the two groups.
The international prostate symptom score (IPSS), quality of life (QOL), and overactive bladder symptom score (OABSS), Q, pulmonary vascular resistance (PVR), daytime urination frequency, urgent urination frequency, urge urinary incontinence frequency and night urinary frequency of both groups improved after treatment, and the difference had statistical significance (P<0.05). The differences of the observation indexes (except PVR) in the observation group before and after treatment was significantly different with those of the control group (P<0.05). The incidence of adverse reactions in the observation group was lower than that in the control group, but the difference had no statistical significance (X=2.843, P>0.05).
Treating benign prostatic hyperplasia in combination with overactive bladder with tamsulosin in combination with solifenacin is more effective than tamsulosin, without significantly increasing adverse reactions. Thus the therapy is worth clinical promotion.
分析坦索罗辛与索利那新联合治疗良性前列腺增生合并膀胱过度活动症的临床疗效及其安全性。另一个目的是探讨大剂量坦索罗辛治疗良性前列腺增生合并膀胱过度活动症的临床疗效及安全性。
选取滨州市人民医院泌尿外科收治的124例确诊为良性前列腺增生（BPH）合并膀胱过度活动症的患者，随机分为两组。对照组62例患者采用坦索罗辛治疗，观察组62例患者采用坦索罗辛联合索利那新治疗。两组治疗均持续12周。比较两组的疗效及不良反应。
两组治疗后国际前列腺症状评分（IPSS）、生活质量（QOL）、膀胱过度活动症症状评分（OABSS）、Q、肺血管阻力（PVR）、日间排尿次数、急迫性排尿次数、急迫性尿失禁次数及夜间排尿次数均改善，差异有统计学意义（P<0.05）。观察组治疗前后观察指标（PVR除外）与对照组比较差异有统计学意义（P<0.05）。观察组不良反应发生率低于对照组，但差异无统计学意义（X=2.843，P>0.05）。
坦索罗辛联合索利那新治疗良性前列腺增生合并膀胱过度活动症比单用坦索罗辛更有效，且未显著增加不良反应。因此该疗法值得临床推广。
